How many drug targets are there?
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
For the past decade, the number of molecular targets for approved drugs has been debated. Here, we reconcile apparently contradictory previous reports into a comprehensive survey, and propose a consensus number of current drug targets for all classes of approved therapeutic drugs. One striking feature is the relatively constant historical rate of target innovation (the rate at which drugs against new targets are launched); however, the rate of developing drugs against new families is significantly lower. The recent approval of drugs that target protein kinases highlights two additional trends: an emerging realization of the importance of polypharmacology, and also the power of a gene-family-led approach in generating novel and important therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, G-protein-coupled receptors (GPCRs) are influenced by trafficking progress and then internalized in the cell membrane and recycled or degraded.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [127]
In the citing paper
“Covalent molecules may not be able to effectively target GPCRs during this turnover process [127].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [127]
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The Pfam Protein Families Database
Bateman, A. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.276 · Cited by 14,000
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Murzin, A. G., Brenner, S. E., Hubbard, T., & Chothia, C. (1995) · Journal of Molecular Biology · doi:10.1016/s0022-2836(05)80134-2 · Cited by 7,012 · cited 1×
“Patterns in drug targets In order to identify the familial relationships between all drug targets, we analysed the presence of domains, using the SCO”
MethodDrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“drugs acted primarily through only 120 underlying molecular target”
BackgroundSelf-citationThe Pfam protein families database
Bateman, A. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh121 · Cited by 3,127
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967 · cited 1×
“Imatinib, originally developed as a highly selective inhibitor of c-AB”
BackgroundA small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892 · cited 1×
“(and which target association led to its first approval for chronic myeloid leukaemia), has subsequently been discovered to be have significant activity against several other clinically relevant kinases, such as c-KI”
Background
Research works printed but not linked: 1
- Christensen, C. M. The Innovator's Dilemma: When New Technologies Cause Great Firms to Fail (Harvard Business School Press, Cambridge, 1997).
Cited by
Items 801–900 of 1,024
Lipids Alter Rhodopsin Function via Ligand-like and Solvent-like Interactions
Salas-Estrada, L. A., Leioatts, N., Romo, T. D., & Grossfield, A. M. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2017.11.021 · Cited by 54
Claxton, D. P., Kazmier, K. N., Mishra, S., & Mchaourab, H. S. (2015) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2015.07.026 · Cited by 58
Trends in Modern Drug Discovery
Eder, J., & Herrling, P. L. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_20 · Cited by 70
Simulations of Biased Agonists in the β2 Adrenergic Receptor with Accelerated Molecular Dynamics
Tikhonova, I. G., Selvam, B., Ivetac, A., Wereszczynski, J., & McCammon, J. A. (2013) · Biochemistry · doi:10.1021/bi400499n · Cited by 61
Kolb, P., Phan, K., Gao, Z., Marko, A. C., Šali, A., & Jacobson, K. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049910 · Cited by 59
“around one third of present day drugs [1].”
BackgroundMethodInfluentialEnsemble of G Protein-Coupled Receptor Active States
Park, P. S.-H. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712799320619 · Cited by 69
“The largest family of membrane proteins, and also one of the largest groups of therapeutic targets, is the G protein-coupled receptor (GPCR) superfamily [1-3].”
BackgroundAl-Alem, L., Southard, R. C., Kilgore, M. W., & Curry, T. E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016179 · Cited by 59
“Indeed, about 13% of the drugs currently on the market target nuclear receptors [6].”
A Chemogenomic Analysis of Ionization Constants—Implications for Drug Discovery
Manallack, D. T., Prankerd, R. J., Nassta, G. C., Ursu, O., Oprea, T. I., & Chalmers, D. K. (2013) · ChemMedChem · doi:10.1002/cmdc.201200507 · Cited by 53
Lopes, J. P., Morató, X., Souza, C., Pinhal, C. M., Machado, N., Canas, P., Silva, H., Štagljar, I., Gandía, J., Fernández-Dueñas, V., et al. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13109 · Cited by 50
C5a-Stimulated Recruitment of β-Arrestin2 to the Nonsignaling 7-Transmembrane Decoy Receptor C5L2
van Lith, L. H. C. J., Oosterom, J., van Elsas, A., & Zaman, G. J. R. (2009) · SLAS DISCOVERY · doi:10.1177/1087057109341407 · Cited by 53
Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function
Ulloa‐Aguirre, A., Zariñán, T., Dias, J. A., & Conn, P. M. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.06.024 · Cited by 58
“This particular type of receptors plays essential roles on a wide range of biological functions (Ulloa-Aguirre and Conn, 2009), and because of their relevance in function and as a cause of disease, they are important therapeutic targets for an array of diseases, as reflected by the fact that ~60–70% of all approved dr…”
Background“Canonical and non-canonical actions of GRK5 in the heart”
Traynham, C. J., Hullmann, J. E., & Koch, W. J. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.01.027 · Cited by 56
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript Non-canonical localization of GRK5 in the nucleus of cells While the canonical role of GRKs is to phosphorylate agonist bound GPCRs located within the plasma membrane, members of the GRK4 subfamily have been found to localize to the nucleu…”
BackgroundInfluentialPredictive features of ligand‐specific signaling through the estrogen receptor
Nwachukwu, J. C., Srinivasan, S., Zheng, Y., Wang, S., Min, J., Dong, C., Liao, Z., Nowak, J., Wright, N. A., Houtman, R., et al. (2016) · Molecular Systems Biology · doi:10.15252/msb.20156701 · Cited by 55
“…tissue- or pathwayspecific signaling outcomes, which is called selective modulation, functional selectivity, or biased signaling, through structural mechanisms that are poorly understood (Frolik et al, 1996; Nettles & Greene, 2005; Overington et al, 2006; Katritch et al, 2012; Wisler et al, 2014).”
BackgroundZhang, K., Li, P., He, Y., Bo, X., Li, X., Li, D., Chen, H., & Xu, H. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.05.014 · Cited by 54
Targeting Long Noncoding RNA with Antisense Oligonucleotide Technology as Cancer Therapeutics
Zhou, T., Kim, Y., & MacLeod, A. R. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3378-5_16 · Cited by 58
Proteomics Tracing the Footsteps of Infectious Disease
Greco, T. M., & Cristea, I. M. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o116.066001 · Cited by 62
“In fact, about two-thirds of existing drugs target cell surface proteins (69).”
BackgroundSerial Femtosecond Crystallography of G Protein–Coupled Receptors
Stauch, B., & Cherezov, V. (2018) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-070317-033239 · Cited by 62
“(38, 99) and are therefore important drug targets; over 30% of all prescription drugs on the market act via these receptors (76, 81).”
BackgroundRunx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression
Gowda, P. S., Wildman, B. J., Trotter, T. N., Xu, X., Hao, X., Hassan, M. Q., & Yang, Y. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0606 · Cited by 52
“Unfortunately, transcription factors are often considered to be non-druggable, as targeting these intracellular proteins lacking enzymatic activity remains challenging (11, 12).”
BackgroundTowards an Optimal Sample Delivery Method for Serial Crystallography at XFEL
Cheng, R. (2020) · Crystals · doi:10.3390/cryst10030215 · Cited by 61
“Membrane proteins including G-protein-coupled receptors (GPCRs), solute carrier (SLCs) and ligand/voltage-gated ion channels account for 30% of the human genome [22] but are the targets of more than 50% of marketed drugs [23].”
BackgroundThe tissue proteome in the multi-omic landscape of kidney disease
Rinschen, M. M., & Sáez-Rodríguez, J. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00348-5 · Cited by 57
Integrative modeling of membrane-associated protein assemblies
Roel‐Touris, J., Jiménez‐García, B., & Bonvin, A. M. J. J. (2020) · Nature Communications · doi:10.1038/s41467-020-20076-5 · Cited by 56
Li, M., Hays, F. A., Roe-Zurz, Z., Vuong, L., Kelly, L., Ho, C.-M., Robbins, R. M., Pieper, U., O’Connell, J. D., Miercke, L. J. W., et al. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.11.021 · Cited by 53
“Underscoring their importance and relevance is that approximately 60% of currently available therapeutics interact with one or more membrane proteins.(1) Studying membrane proteins has proven to be experimentally daunting.”
BackgroundDas, M., Du, Y., Ribeiro, O., Hariharan, P., Mortensen, J. S., Patra, D., Skiniotis, G., Loland, C. J., Guan, L., Kobilka, B. K., et al. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b11997 · Cited by 52
Chemoproteomics, A Broad Avenue to Target Deconvolution
Gao, Y., Ma, M., Li, W., & Lei, X. (2023) · Advanced Science · doi:10.1002/advs.202305608 · Cited by 61
Wallach, I., Jaitly, N., & Lilien, R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012063 · Cited by 53
“augmented that method by adding an evolutionary model to account for protein sequence homology. A substantial limitation of these two approaches is their reliance on the availability of a 3D structure of the primary target. Thus, this method may not be feasible when studying many popular drug targets”
MethodGroot‐Kormelink, P. J., Fawcett, L., Wright, P. D., Gosling, M., & Kent, T. C. (2012) · BMC Immunology · doi:10.1186/1471-2172-13-57 · Cited by 52
“G-protein coupled receptors (GPCRs) and ion channels are large families of cell surface proteins and together comprise the molecular target of approximately 40% of all FDA approved drugs [5].”
BackgroundSpinal NTS2 receptor activation reverses signs of neuropathic pain
Tétreault, P., Beaudet, N., Perron, A., Belleville, K., René, A., Cavelier, F., Martínez, J., Stroh, T., Jacobi, A. M., Rose, S. D., et al. (2013) · The FASEB Journal · doi:10.1096/fj.12-225540 · Cited by 59
“(57), of the 266 human targets of FDA-approved drugs, 27% correspond to the rhodopsin-like family of GPCRs.”
BackgroundRoles of transcriptional factor 7 in production of inflammatory factors for lung diseases
Zhu, Y., Wang, W. Y., & Wang, X. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0617-7 · Cited by 60
“Mutations of transcription factors were found in human diseases, and were considered as drugable targets for drug discovery and development [8, 9].”
BackgroundHolliday, N. D., Watson, S., & Brown, A. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2011.00112 · Cited by 53
“As the largest family of cell surface receptors in man, GPCRs have proved tractable drug targets in the past (Overington et al., 2006).”
BackgroundCancer immunotherapy via nucleic acid aptamers
Khedri, M., Rafatpanah, H., Abnous, K., Ramezani, P., & Ramezani, M. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.10.013 · Cited by 55
Distinctive Behaviors of Druggable Proteins in Cellular Networks
Mitsopoulos, C., Schierz, A. C., Workman, P., & Al-Lazikani, B. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004597 · Cited by 53
“Firstly, the positive ‘drug target list’ is a list of manually-curated targets of FDA-approved pharmaceuticals [32,34], defined using strict criteria based on known pharmacological action and drug approval information.”
BackgroundMethodSelf-citationRational design and validation of a vanilloid-sensitive TRPV2 ion channel
Yang, F., Vu, S., Yarov-Yarovoy, V. M., & Zheng, J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604180113 · Cited by 60
Nguyen, A. T. N., Vecchio, E. A., Thomas, T., Nguyen, T. D., Aurelio, L., Scammells, P. J., White, P. J., Sexton, P. M., Gregory, K. J., May, L. T., et al. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.105015 · Cited by 57
Yuan, X., Raniolo, S., Limongelli, V., & Xu, Y. (2018) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.8b00046 · Cited by 56
Du, Y., Song, W., Chen, J., Chen, H. H., Xuan, Z., Zhao, L., Chen, J., Jin, C., Zhou, M., Tuo, B., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32121 · Cited by 53
“could cure many human diseases, including cardiovascular and neurological diseases.(4) The potassium channel KCa3.”
BackgroundAshtawy, H. M., & Mahapatra, N. R. (2012) · IEEE/ACM Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2012.36 · Cited by 53
How Carvedilol activates β2-adrenoceptors
Benkel, T., Zimmermann, M., Zeiner, J., Bravo, S., Merten, N., Lim, V., Matthees, E. S. F., Drube, J., Miess, E., Malan, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34765-w · Cited by 62
“use 6,7 . β ARs are also among the most powerful regulators of cardiac function 8 , and the primary targets for the endogenous catecholamines adrenaline and noradrenaline, which act as neurotransmitters and hormones to control heart rate and blood pressure 9 . β -blockers -blockers oppose the…”
BackgroundResultGPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity
Fyfe, M. C. T., McCormack, J. G., Overton, H. A., Procter, M. J., & Reynet, C. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.4.403 · Cited by 55
“Modulators of G-protein-coupled receptors (GPCRs), which represent one of the most successful target classes in drug discovery [5,6] , have been identified as prime candidates for new treatments for type 2 diabetes and associated disorders [7,8] .”
BackgroundArooj, M., Sakkiah, S., Cao, G. P., & Lee, K. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060470 · Cited by 57
Targeting Glioblastoma Stem Cells: Cell Surface Markers
He, J., Liu, Y., & Lubman, D. M. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712804485944 · Cited by 54
Design-rules for stapled peptides with in vivo activity and their application to Mdm2/X antagonists
Chandramohan, A., Josien, H. B., Yuen, T. Y., Duggal, R., Spiegelberg, D., Yan, L. Y., Juang, Y.-C. A., Ge, L., Aronica, P. G. A., Kaan, H. Y. K., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-43346-4 · Cited by 65
Dynamic ligand binding dictates partial agonism at a G protein–coupled receptor
Böck, A., Chirinda, B., Krebs, F., Messerer, R., Bätz, J., Muth, M., Dallanoce, C., Klingenthal, D., Tränkle, C., Hoffmann, C., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1384 · Cited by 51
Techniques for recording reconstituted ion channels
Demarche, S. F., Sugihara, K., Zambelli, T., Tiefenauer, L., & Vörös, J. (2011) · The Analyst · doi:10.1039/c0an00828a · Cited by 54
Global Analysis of Small Molecule Binding to Related Protein Targets
Krüger, F. A., & Overington, J. P. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002333 · Cited by 56
“often organized conceptually around pharmacologically successful gene families (such as nuclear receptors, rhodopsin-like GPCRs, various ion-channel families, and most recently, protein kinases) [4,5], leveraging known data to develop novel selective chemotypes is of fundamental importance.”
BackgroundSelf-citationVisualizing the drug target landscape
Campbell, S. J., Gaulton, A., Marshall, J., Bichko, D., Martin, S., Brouwer, C., & Harland, L. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.09.011 · Cited by 59
Developments in SPR Fragment Screening
Chavanieu, A., & Pugnière, M. (2016) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1160888 · Cited by 51
“Several developments of SPR were recently reported or adapted for FBDD screenings on important and challenging therapeutic targets.[50,51] These improvements concern the enhanced stability of the immobilized targets, the characterization of the nature of orthosteric or allosteric binding sites and the correlation with…”
Reconstitution of Human Ether-a-go-go-Related Gene Channels in Microfabricated Silicon Chips
Oshima, A., Hirano‐Iwata, A., Mozumi, H., Ishinari, Y., Kimura, Y. N., & Niwano, M. (2013) · Analytical Chemistry · doi:10.1021/ac303484k · Cited by 51
Jang, H. S., Hong, K., & Choi, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061221 · Cited by 54
“Melatonin receptors are G protein-coupled receptors, which play an important role in various cellular processes and drug responses [125].”
BackgroundNMR-Fragment Based Virtual Screening: A Brief Overview
Singh, M., Tam, B., & Akabayov, B. (2018) · Molecules · doi:10.3390/molecules23020233 · Cited by 57
“Computational chemistry tools are used to explore larger commercially available fragment databases and can significantly improve the efficiency of the individual steps of FBDD, such as fragment library design, active site categorization, fragment hit discovery, and hit-to-lead-to-candidate optimization [125].”
MethodApplication of computational methods for anticancer drug discovery, design, and optimization
Prada‐Gracia, D., Huerta‐Yépez, S., & Moreno‐Vargas, L. M. (2016) · Boletín Médico Del Hospital Infantil de México (English Edition) · doi:10.1016/j.bmhime.2017.11.040 · Cited by 58
Das, D., & Goyal, A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8005-1_15 · Cited by 51
Molecular Mechanisms Underlying Heart Failure and Their Therapeutic Potential
Fonseka, O., Gare, S. R., Chen, X., Zhang, J., Alatawi, N. H. O., Ross, C., & Liu, W. (2025) · Cells · doi:10.3390/cells14050324 · Cited by 54
Tactical Approaches to Interconverting GPCR Agonists and Antagonists
Dosa, P. I., & Amin, E. A. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00982 · Cited by 56
Improving drug safety: From adverse drug reaction knowledge discovery to clinical implementation
Tan, Y., Hu, Y. Q., Liu, X., Yin, Z., Chen, X.-W., & Liu, M. (2016) · Methods · doi:10.1016/j.ymeth.2016.07.023 · Cited by 56
“The most common drug targets are proteins, however, some nucleic acids can also serve as drug targets [15].”
BackgroundAn overview of Ca2+mobilization assays in GPCR drug discovery
Ma, Q., Ye, L., Liu, H., Shi, Y., & Zhou, N. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1303473 · Cited by 57
Inside Job: Methods for Delivering Proteins to the Interior of Mammalian Cells
Bruce, V. J., & McNaughton, B. R. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.06.014 · Cited by 57
“While small molecules will likely always play a prominent role in pharmaceutical science, most protein receptors lack well-defined small-molecule binding sites, and thus challenge or evade small-molecule recognition (Overington et al., 2006).”
BackgroundTóth, A. D., Prokop, S., Gyombolai, P., Várnai, P., Balla, A., Gurevich, V. V., Hunyady, L., & Turu, G. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.813139 · Cited by 53
“The family of G protein– coupled receptors (GPCRs)(3) consists of 800 members in humans and about 30% of modern drugs target these molecules (1).”
BackgroundUniversality of the Sodium Ion Binding Mechanism in Class A G‐Protein‐Coupled Receptors
Selvam, B., Shamsi, Z., & Shukla, D. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201708889 · Cited by 52
Be Cautious with Crystal Structures of Membrane Proteins or Complexes Prepared in Detergents
Guo, Y. (2020) · Crystals · doi:10.3390/cryst10020086 · Cited by 60
The RGS protein inhibitor CCG-4986 is a covalent modifier of the RGS4 Gα-interaction face
Kimple, A. J., Willard, F. S., Giguère, P. M., Johnston, C. A., Mocanu, V., & Siderovski, D. P. (2007) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.06.002 · Cited by 50
“The single largest class of pharmaceuticals currently prescribed are those that target G proteincoupled receptor (GPCR) signaling pathways [1,2].”
BackgroundLarge-scale reverse docking profiles and their applications
Lee, M., & Kim, D. (2012) · BMC Bioinformatics · doi:10.1186/1471-2105-13-s17-s6 · Cited by 53
“The “druggability” of a certain target protein represents how probable the protein is in fact a real target of drugs, and it has been investigated in many previous studies [14-16].”
Zhu, F., Han, L., Zheng, C., Xie, B., Tammi, M. T., Yang, S., Wei, Y., & Chen, Y. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.149955 · Cited by 50
“…neural disorders, arthritis, diabetes, and obesity, which suggests at A SPE T Journals on M arch 6, 2015 jpet.aspetjournals.org D ow nloaded from that these families continue to be attractive sources for target discovery (Zambrowicz and Sands, 2003; Overington et al., 2006; Zheng et al., 2006a,b).”
BackgroundRajakumara, E., Abhishek, S., Nitin, K., Saniya, D., Bajaj, P., Schwaneberg, U., & Davari, M. D. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00500 · Cited by 49
The REV-ERB Nuclear Receptors: Timekeepers for the Core Clock Period and Metabolism
Adlanmérini, M., & Lazar, M. A. (2023) · Endocrinology · doi:10.1210/endocr/bqad069 · Cited by 57
Maltose neopentyl glycol-3 (MNG-3) analogues for membrane protein study
Cho, K. H., Husri, M. N., Amin, A., Gotfryd, K., Lee, H. J., Go, J., Kim, J. W., Loland, C. J., Guan, L., Byrne, B., et al. (2015) · The Analyst · doi:10.1039/c5an00240k · Cited by 49
Lipid bilayer technologies in ion channel recordings and their potential in drug screening assay
Kongsuphol, P., Fang, K. B., & Ding, Z. (2013) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2013.04.119 · Cited by 49
Heeres, J. T., & Hergenrother, P. J. (2011) · Chem. Soc. Rev. · doi:10.1039/b923660k · Cited by 49
Elucidation of the binding preferences of peptide recognition modules: SH3 and PDZ domains
Teyra, J., Sidhu, S. S., & Kim, P. M. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.05.043 · Cited by 54
“Novel drugs developed in the past decade have almost solely focused on G protein-couple receptors (GPCRs) and protein kinases, presumably because of the high cost and risk associated with novel drug development [79].”
BackgroundShenkarev, Z. O., Lyukmanova, E. N., Butenko, I., Petrovskaya, L. E., Paramonov, A. S., Shulepko, M. A., Nekrasova, O. V., Kirpichnikov, M. P., & Arseniev, A. S. (2012) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2012.11.005 · Cited by 49
May, L. T., Self, T. J., Briddon, S. J., & Hill, S. J. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064493 · Cited by 153
“However, GPCRs also contain allosteric binding sites (that is, any receptor binding site that is topographically distinct from the orthosteric site) (May et al., 2007b).”
BackgroundInfluentialTREK-King the Blood–Brain-Barrier
Bittner, S., Ruck, T., Fernández‐Orth, J., & Meuth, S. G. (2014) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-014-9530-8 · Cited by 52
“In NMO, which is an inflammatory demyelinating disorder of the CNS, serum autoantibodies specifically target external epitopes of AQP4 (Papadopoulos and Verkman 2012).”
InfluentialBarneh, F., Jafari, M., & Mirzaie, M. (2015) · Briefings in Bioinformatics · doi:10.1093/bib/bbv094 · Cited by 53
Stark, H., & Chari, A. (2015) · Microscopy · doi:10.1093/jmicro/dfv367 · Cited by 49
Abou-Gharbia, M. A., & Childers, W. E. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401564r · Cited by 58
Lau, C. H. Y., King, G. F., & Mobli, M. (2016) · Scientific Reports · doi:10.1038/srep34333 · Cited by 49
High-throughput electrophysiological assays for voltage gated ion channels using SyncroPatch 768PE
Li, T., Lu, G., Chiang, E. Y., Chernov-Rogan, T., Grogan, J. L., & Chen, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180154 · Cited by 52
Conte, M., Lupette, J., Seddiki, K., Meï, C., Dolch, L.-J., Gros, V., Barette, C., Rébeillé, F., Jouhet, J., & Maréchal, É. (2018) · PLANT PHYSIOLOGY · doi:10.1104/pp.17.01804 · Cited by 58
Ion Channel Contributions to Wing Development in Drosophila melanogaster
George, L. F., Pradhan, S. J., Mitchell, D. N., Josey, M., Casey, J. T., Belus, M. T., Fedder-Semmes, K. N., Dahal, G. R., & Bates, E. A. (2019) · G3 Genes Genomes Genetics · doi:10.1534/g3.119.400028 · Cited by 57
“Depolarization of these cells results in eye malformation while hyperpolarization of non-eye cells can induce the formation of ectopic eyes (Pai et al. 2012).”
BackgroundYin, J., Chen, X., Wang, C.-C., Zhao, Y., & Sun, Y. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00384 · Cited by 49
Serendipity in anticancer drug discovery
Hargrave-Thomas, E., Yu, B., & Reynisson, J. (2012) · World Journal of Clinical Oncology · doi:10.5306/wjco.v3.i1.1 · Cited by 50
Rawson, S., Davies, S. P., Lippiat, J. D., & Muench, S. P. (2016) · Molecular Membrane Biology · doi:10.1080/09687688.2016.1221533 · Cited by 56
“ARTICLE HISTORY Received 14 June 2016 Revised 14 July 2016 Accepted 19 July 2016 KEYWORDS Electron microscopy; membrane protein; protein structure”
BackgroundMethodChoi, H. Y., Saha, S. K., Kim, K., Kim, S., Yang, G., Kim, B., Kim, J., & Cho, S. (2015) · BMB Reports · doi:10.5483/bmbrep.2015.48.2.250 · Cited by 55
“GPCRs bind and regulate the effects of 80% of all hormones in the body and account for 20-50% of the pharmaceuticals on the current market (9).”
BackgroundLeguèbe, M., Nguyen, C., Capece, L., Zung, H., Giorgetti, A., & Carloni, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047332 · Cited by 50
“Human GPCRs are among the most important targets of pharmaceutical intervention, constituting the target for ,30% of clinically used drugs [2].”
BackgroundPerry, S. L., Guha, S., Pawate, A. S., Bhaskarla, A. V., Agarwal, V., Nair, S. K., & Kenis, P. J. A. (2013) · Lab on a Chip · doi:10.1039/c3lc50276g · Cited by 48
Pharmacological screening technologies for venom peptide discovery
Prashanth, J. R., Hasaballah, N. H., & Vetter, I. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.03.038 · Cited by 49
“(Overington et al., 2006).”
A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor
Licciardello, M. P., Ringler, A., Markt, P., Klepsch, F., Lardeau, C.-H., Sdelci, S., Schirghuber, E., Müller, A. C., Caldera, M., Wagner, A., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2382 · Cited by 54
Lipid environment of membrane proteins in cryo-EM based structural analysis
Mio, K., & Sato, C. (2017) · Biophysical Reviews · doi:10.1007/s12551-017-0371-6 · Cited by 54
“Indeed, 50–60% of drugs on the market target membrane proteins, such as G protein-coupled receptors and ion channels (Drews 2000; Overington et al. 2006; Terstappen and Reggiani 2001).”
BackgroundWu, J., Zhang, Q., Wu, W., Pang, T., Hu, H., Chan, W. K. B., Ke, X., & Zhang, Y. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty070 · Cited by 54
Cryopreserved cells facilitate cell-based drug discovery
Zaman, G. J. R., de Roos, J. A. D. M., Blomenröhr, M., van Koppen, C. J., & Oosterom, J. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.05.008 · Cited by 48
Ballester, P. J., & Mitchell, J. B. O. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200057e · Cited by 48
Systematic illumination of druggable genes in cancer genomes
Jiang, J., Yuan, J., Hu, Z., Zhang, Y., Zhang, T., Xu, M., Long, M., Fan, Y., Tanyi, J. L., Montone, K. T., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110400 · Cited by 45
“…estimated to be part of PDGs whose activities may be modulated by pharmaceuticals (Brown et al., 2018; Campbell et al., 2012; Finan et al., 2017; Hopkins and Groom, 2002; Kumar et al., 2013; Overington et al., 2006; Rask-Andersen et al., 2011, 2014; Russ and Lampel, 2005; Southan et al., 2015).”
Expression Specificity of Disease-Associated lncRNAs: Toward Personalized Medicine
Nguyen, Q. H., & Carninci, P. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_464 · Cited by 55
Diculescu, V. C., & Oliveira‐Brett, A. M. (2015) · Bioelectrochemistry · doi:10.1016/j.bioelechem.2015.10.004 · Cited by 47
Carpino, P. A., & Goodwin, B. J. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2010.533171 · Cited by 54
“A majority of the targets with ‡ 5 applications are either enzymes or GPCRs, with the latter drug class representing ~ 25% of marketed drugs [12].”
BackgroundRetinal Conformation Governs pKaof Protonated Schiff Base in Rhodopsin Activation
Zhu, S., Brown, M. F., & Feller, S. E. (2013) · Journal of the American Chemical Society · doi:10.1021/ja4002986 · Cited by 52
Evaluating DAPK as a therapeutic target
Huang, Y., Chen, L., Guo, L., Hupp, T. R., & Lin, Y. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0919-2 · Cited by 49
“[2] investigated the targets of approved drugs and discovered a surprisingly small cohort of only 324 targets, in comparison to the predicted nearly 21,000 coding genes in human genome [3].”
BackgroundProbing G Protein-Coupled Receptor—Ligand Interactions with Targeted Photoactivatable Cross-Linkers
Grunbeck, A., & Sakmar, T. P. (2013) · Biochemistry · doi:10.1021/bi401300y · Cited by 47
Ionotropic Glutamate Receptors: Regulation by G-Protein-Coupled Receptors
Rojas, A., & Dingledine, R. J. (2013) · Molecular Pharmacology · doi:10.1124/mol.112.083352 · Cited by 51
“Over 40% of FDA-approved drugs target either G-protein coupled receptors (GCPR) or ion channels (Overington et al., 2006).”
BackgroundNuclear receptors and chromatin: an inducible couple
Gadaleta, R. M., & Magnani, L. (2013) · Journal of Molecular Endocrinology · doi:10.1530/jme-13-0170 · Cited by 61
Wang, C., Hu, G., Wang, K., Bryliński, M., Xie, L., & Kurgan, L. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv597 · Cited by 50
Metadata
- Authors
- Overington, J. P., Al-Lazikani, B., & Hopkins, A. L.
- Affiliations
- Pfizer (United Kingdom) (GB)
- Corresponding author
- Overington, John P.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-12
- Volume
- 5
- Issue
- 12
- Pages
- 993-996
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1968682237
- Cited by
- 3,505
- References
- 29
- Citations by year
- 2026: 82 · 2025: 126 · 2024: 117 · 2023: 127 · 2022: 173 · 2021: 168 · 2020: 190 · 2019: 190 · 2018: 198 · 2017: 215 · 2016: 276 · 2015: 268 · 2014: 245 · 2013: 280 · 2012: 247
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- therapeutic target, molecular targets, protein kinases, polypharmacology, approved drugs
- MeSH terms
- Humans, Technology, Pharmaceutical, Drug Design, Drugs, Investigational, Genome, Human, Drug Delivery Systems, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.